<DOC>
	<DOC>NCT01744665</DOC>
	<brief_summary>To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5</brief_summary>
	<brief_title>Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<criteria>Diagnosis of CML Treated with at least 1 year of imatinib BcrAbl level by PCR must be less than or equal to 0.1% and greater than 0.0032% by PCR reported on the International scale. This will be confirmed during screening Written informed consent obtained prior to any screening procedures performed T315I mutation Prior imatinib failure or had accelerated phase or blast crisis CML Impaired cardiac function (defined futher in the protocol) Pregnant or lactating women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl</keyword>
</DOC>